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Summary 
Reversible airway hyperreactivity underlies the pathophysiology of asthma, yet the precise me- 
diators of the response remain unclear. Human studies have correlated aberrant activation of T 
helper (Th) 2-like effector systems in the airways with disease.  A routine model of airway hy- 
perreactivity in response to acetylcholine was established using mice immunized with ovalbu- 
rain  and  challenged with aerosolized antigen.  No  airway hyperreactivity occurred in severe 
combined immunodeficient mice. Identically immunized BALB/c mice developed an influx of 
cells, with a predominance of eosinophils and CD4 + T  cells, into the lungs and bronchoalveo- 
lar lavage fluid at the time that substantial  changes in airway pressure and resistance were quan- 
titated. Challenged animals  developed marked increases in Th2 cytokine production, eosino- 
phil  influx,  and serum immunoglobulin  E  levels.  Neutralization of interleukin  (IL)  4  using 
monoclonal antibodies administered during the period of systemic immunization abrogated air- 
way hyperreactivity but had little effect on the influx of eosinophils. Administration of anti- 
IL-4 only during the period of the aerosol challenge did not affect the subsequent response to 
acetylcholine. Finally, administration  of anti-IL-5 antibodies at levels that suppressed eosino- 
phils to < 1% of recruited cells had no effect on the subsequent airway responses. BALB/c mice 
had significantly greater airway responses than C57BL/6 mice, consistent with enhanced IL-4 
responses to  antigen in BALB/c mice. Taken  together, these data implicate  IL-4 generated 
during the period of lymphocyte priming with antigen in establishing the cascade  of responses 
required to generate airway hyperreactivity to inhaled antigen. No role for IL-5 or eosinophils 
could be demonstrated. 
A 
sthma is one of the common chronic lung diseases of 
industrialized countries. Despite effective therapy, treat- 
ment costs,  toxicity, and the need for coordinated delivery 
of medication limit the benefits of current regimens. Strate- 
gies designed to prevent asthma in high-risk individuals, or 
that  reverse the  pathologic  processes that lead  to  asthma, 
could be far more effective than current interventions. Un- 
fortunately, development of such strategies  has been ham- 
pered by a lack of basic  understanding of the pathogenesis 
of the disease. 
Reversible airway narrowing,  the  physiologic hallmark 
of asthma, is often seen in association with evidence of im- 
mune system activation, including T cell and eosinophil in- 
filtration of the  airways.  Evidence for Th2  cytokine pro- 
duction,  including  IL-4  and  IL-5,  and  effector function, 
such as eosinophil infiltration and elevated levels of IgE, has 
been reported (1-8). A number of secondary inflammatory 
mediators,  particularly mast  cell and  eosinophil products, 
have been shown to induce physiologic changes similar to 
asthma or to cause smooth muscle contraction in vitro (9, 
10).  However,  little  direct  experimental  evidence  exists 
that clearly identifies the principal pathogenic cells and me- 
diators of this complex inflammatory cascade. 
Murine models of airway hyperreactivity have been used 
to begin to identify components of the immune response, 
although  the  imanunology,  cellular response,  and  airway 
physiology  have  infrequently  been  coordinately  investi- 
gated  (11-18).  We  have  established a  murine  model and 
used this to elucidate critical cellular and cytokine require- 
ments for the acute airway changes induced by exposure to 
antigen.  Surprisingly,  these data  fail  to support a  role for 
two prominent components of the inflammatory response, 
eosinophils and IL-5, and emphasize the need for integra- 
tion of immunologic and physiologic studies. 
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Immunization  Protocol.  BALB/c,  C57BL/6,  and C.B-17/scid 
mice were purchased from the Jackson Laboratory (Bar Harbor, 
ME). Mice were inmmnized with 25 ~g turkey egg OVA (Sigma 
Chemical Co., St. Louis, MO) adnfinistered subcutaneously with 
alum weekly for 4 wk and subsequently exposed to two or three 
aerosolizations 5 d apart of OVA or an unrelated immunodomi- 
nant antigen from  the  protozoan  Leishmania  major  (19).  Aero- 
solization of antigens was  performed  using a  nose-only aerosol 
chamber adapted  for mice  (Intox Products,  Albuquerque, NM) 
coupled  to  a  nebulizer  (Aerotech  II;  CIS-US,  Bedford,  MA) 
driven by compressed air at a flow rate of 10 liters/min. Under 
these conditions, aerosol particles have a median aerodynamic di- 
ameter of 1.4 0.m as measured by a cascade impactor (Intox Prod- 
ucts).  Antigen was delivered over 20 min at a concentration of 50 
rag/nil in PBS. Designated groups of mice received Img neutral- 
izing anti-lL-4 mAb (11B11; rat IgG1; reference 20) intraperito- 
neally weekly,  either  throughout  the  experimental protocol  or 
limited to the aerosolization period, as denoted; or a combination 
of 1 ~Lg each of two neutralizing anti-IL-5 mAbs (TRFK-4 and 
TILFK-5; rat lgG2a and IgGl, respectively; reference 21)  intra- 
peritoneally weekly throughout the experimental period,  lsotype 
control antibodies Y13-259  (rat  lgG1)  and u  (rat  lgG2a) 
were adnfinistered to control groups. 
Determination ofAinvay Phj,siology.  24 h after the final aerosol 
exposure,  mice  were  anesthetized  with  pentobarbital  (Abbott 
Laboratories, North Chicago, IL; 50 mg/kg intraperitoneally) and 
the tracheas were surgically exposed,  cannulated, and connected 
to a rodent ventilator (Harvard Apparatus, South Natick, MA) with 
an in-line pressure transducer (Pd23 inside diameter; Gould, Inc., 
Oxnard, CA). Animals were ventilated with 100% oxygen (9 ~1/ 
g) at  120 breaths/min; under these conditions, naive mice main- 
tain physiologic arterial  blood  gas  parameters  except  for supra- 
physiologic arterial Pao 2 (data not shown). A paralytic agent (pan- 
curonium bromide, 0.1 mg/kg; Gensia Laboratories, lrvine, CA) 
was administered to eliminate spontaneous respirations. After re- 
cording of a stable baseline airway pressure (<5% variation over 3 
min), acetylcholine chloride (Ach; 1 btg/g; Signaa Chemical Co.) 
was infused intravenously over I s via the tail vein and the change 
in airway pressure recorded over 3  min on a standard polyg-raph 
(Grass Instrument Co., Quincy, MA). Final airway pressure changes 
were  recorded as the maximum percentage of change in airway 
pressure from baseline (maximum airway pressure -  baseline air- 
way pressure/baseline airway pressure). 
To  compare  changes  in airway pressure,  as measured above, 
with changes in resistance, separate groups of comparably treated 
mice were analyzed using a protocol modified from Amdur and 
Mead (22).  Mice were anesthetized and ventilated as above, and a 
27-guage needle was used to  establish intravenous access  in the 
tail vein. Animals were placed inside a plethysmograph coupled to 
a pressure transducer (model MP45; Validyne Engineering Corp., 
Northridge, CA) and constructed with ports for intravenous and 
ventilator access tubing. Lung resistance (R,~) was determined by 
continuously quantitating the  quotient APt/AV  (where  APt  = 
change in tracheal pressure and AV =  change in flow) at points of 
equal lung volume (70%  tidal volume)  using a  pulmonary me- 
chanics analyzer (model 6; Buxco Corp.,  Sharon, CT). APt was 
determined using a pressure transducer (model 267 BC; Sanborn 
Co., Waltham, MA) connected to the tracheal cannnla. To deter- 
mine  AV,  plethysmograph  pressure  changes  were  calibrated  to 
changes in volume over the physiologic range studied. The dif- 
ferential of this value over time is ?iV. After establishing a stable 
baseline tk~  (<5% variation over 3  rain), Ach was administered 
intravenously over 1 s in increasing doses until at least a 50% in- 
crease  in airway pressure and a 200% increase in R~ was obtained. 
The provocative concentration of Ach,  in micrograms Ach per 
gram, that caused a 50% increase in airway pressure (PCs0) and a 
200% increase in 1L  L (PC200) was calculated from interpolation of 
appropriate dose-response curves as described (23). 
Collection of Lung Cells.  Immediately after collection of physi- 
ologic parameters, mice were given 0.1 ml 1:1,000 heparin intra- 
peritoneally and killed by transecting the let~ renal artery for col- 
lection  of  blood.  Bronchoalveolar  lavage  (BAL) I  cells  were 
collected by lavaging whole lung with 3  ml PBS  in 0.5-nil ali- 
quots via the tracheal cannula and withdrawing slowly while gently 
massaging the  thorax.  Whole-lung cells  were  prepared after re- 
moving residual  blood  by  thorough  perfusion  of PBS  via  the 
main puhnonary artery until the lungs were completely blanched. 
The  lungs were  removed  and  minced into  fine fragments  that 
were gently dispersed into PBS using a syringe plunger and passed 
through a 0.75-bml nylon mesh filter. BAL and whole lung cells 
were washed twice, counted, and resuspended at  107 cells/nil in 
RPMI-1640 with 5% fetal bovine serum (FBS;  Hyclone Labora- 
tories Inc., Logan, UT) and antibiotics. 
Analysis  of Cytokine  Transcripts.  Cells were  lysed in RNAzol 
B  (Biotecx Laboratories,  Houston, TX) and RNA extracted ac- 
cording to  the  manufacturer's recommendations. RNA  was  re- 
verse  transcribed with  Moloney murine leukemia virus reverse 
transcriptase  (GIBCO  BRL,  Gaithersburg,  MD)  and  random 
hexamer primers (Promega Corp., Madison, WI). PCtL was per- 
formed  with  a  multiple  cytokine  competitor  construct  as  de- 
scribed (24).  The  construct contains a sequence specific for the 
constitutively expressed gene encoding hypoxanthine phosphori- 
bosyltransferase (HP1LT), allowing adjustments of input cDNA to 
comparable amounts of HPtLT expression. Adjusted cDNAs were 
then amplified with cytokine-specific primers, and the  products 
were  separated  by electrophoresis  in ethidium bromide-stained 
2.5% agarose gels, thus allowing discrimination of the larger coin- 
petitor construct from the wild-D,pe cDNAs that migrate further 
in the gel. Photographic negatives of the gels were scanned with 
an imaging densitometer to quantitate band intensities and con- 
firm visual interpretations. 
FACS  |  Analysis.  10  s cells  were stained with PE-conjugated 
anti-CD4, FITC-conjugated anti-CD8, and FITC-conjugated anti- 
B220 mAbs (PharMingen, San Diego, CA) and analyzed for sur- 
face  expression by cytofluorimetry (FACScan|  Becton  Dickin- 
son 8: Co., Mountain View, CA). 
Cell Differentials.  1-5  ￿  103 cells  were spun onto glass slides 
(Cytospin 2; Shandon Instruments, Inc., Astmoor, UK), air dried, 
fixed with methanol, and stained with Diff-Quik (Baxter Health- 
care  Corp.,  Miami.  FL).  Eosinophils and  macrophages/mono- 
cytes were enumerated based on nmrphology and staining char- 
acteristics  and expressed as percentages of total cells.  Eosinophil 
counts  were  confirmed  with  phloxine  B  staining  (Unopette; 
Beckton Dickinson & Co.). 
ELISPOT Assa},s.  Single-cell suspensions from  whole  lung 
cells were distributed in duplicate aliquots (10  ~ cells in 100  ILl of 
RPMI-1640 with 5% FBS and antibiotics) into 96-well microti- 
ter plates  (lmmulon IV; Dynatech Laboratories,  Inc., Chantilly, 
VA)  that  had  been precoated  with  either  mAb BVD4-1Dll.2 
against IL-4 or mAb 1L46A2 against IFN-% Serial threefold dilu- 
1Abbreviations used in this paper: Ach, acetylcholine chloride; BAL, bron- 
choalveolar lavage; ELISPOT,  enzyme-hnked immunospot assay; FBS, 
fetal bovine serum: HPILT, hypoxanthine phospboribosyl transferase. 
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for 8 h at 37~  Wells were washed with PBS to remove cells and 
incubated  with  biotinylated  secondary  antibodies  against  IL-4 
(BVD6-24G.2)  or  [FN-~  (XMG-1.2).  After  1  h,  wells  were 
washed and incubated for 1 h with 100 ~1 ofstreptavidin-conju- 
gated alkaline phosphatase (Jackson ImmunoResearch Laborato- 
ries,  Inc., West Grove, PA) in PBS with 0.05% Tween 20 and 
5%  FBS.  Color  was  developed  with  5-bromo-4-chloro-3- 
indolyl phosphate in 0.1 M  2-amino-2-methyl-l-propanol buffer 
(Sigma  Chemical Co.) suspended in 0.6%  agarose  (Sea-Plaque; 
FMC Bioproducts Inc., Rockland, ME).  After solidification  of 
the agar, individual blue spots were counted by inverted micros- 
copy. 
Antibody Isotypes.  Total serum  IgE was  quantitated  using a 
double mAb-based sandwich ELISA with antibody B.IE.3 as the 
primary antibody and biotinylated EM-95 as the detecting anti- 
body. Results were quantitated by comparison to a standard con- 
trol (Sigma Chemical Co.). 
Histopathology.  Whole lungs were distended by instillation  of 
4% paraformaldehyde in PBS via the trachea,  removed, and im- 
mersed in the same fixative  with the trachea clamped for 24 h. 
Tissue  was sliced  and embedded in paraffin,  and 5-lxm sections 
were stained  with hematoxylin and eosin for light  microscopic 
examination. 
Results 
Establishing  a  Murine  Model  of Airway  Hyperreactivity. 
Groups  of BALB/c mice  that  had  been  immunized  with 
OVA were challenged with aerosolized OVA, an irrelevant 
antigen,  or saline;  an additional  nonimmunized group was 
challenged with aerosolized OVA.  1 d  after the final aero- 
solization, mice were anesthetized and paralyzed, and, after 
stabilization on a rodent ventilator,  airway pressure and re- 
sistance  were measured after intravenous administration  of 
1  ~g/g  Ach  (Fig.  1).  Mice  immunized  with  OVA  and 
aerosolized with  OVA  demonstrated  a  marked  broncho- 
motor response to Ach and a marked delay in the return to 
baseline airway pressure  that was not present in any of the 
other groups. To assess airway responsiveness by an alterna- 
tive method, airway resistance was measured and compared 
with  simultaneously  calculated  airway  pressure  responses 
(Fig.  2).  High doses of Ach could elicit exaggerated bron- 
chomotor reactivity as assessed by increases in both airway 
pressure  and  resistance  in  control  groups  of mice.  How- 
ever, the dose-response curves were significantly shifted in 
the immunized group challenged with OVA (PCs0:1.7  • 
0.2  and  PC200:1.8  •  0.3  Ixg/g)  compared  with  saline 
(PCs0:6.5  •  1.7 and PC200:6.2  •  0.8  p~g/g; P  =  0.003 
and  0.03,  respectively).  Baseline  values  of airway pressure 
and resistance did not differ significantly between groups of 
mice  before  injection  of Ach.  These  physiologic findings 
were reproducible  in multiple  experiments  and were used 
to define antigen-specific airway hyperreactivity. Results in 
the subsequent experiments are displayed as airway pressure 
changes in response to 1 I~g/g Ach. 
The  requirement  for  antigen  specificity  suggested  by 
these experiments was consistent with a role for cells  of the 
acquired immune system. Immunization and aerosolization 
of SCID  mice,  which  are  deficient  in  T  and  B  cells,  re- 
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Figure  1.  Airway pressure tracings  in  response to  Ach.  BALB/c  or 
SCID mice were untreated  (naive),  immunized with OVA (OVA)  and 
aerosolized  with OVA (OVA~OVA),  immunized with OVA and aero- 
sohzed  with  an  irrelevant  antigen  (OVA/irrelevant  Ag),  or  immunized 
with saline and aerosolized  with OVA (saline~OVA).  After stabilization  of 
airway pressures on a rodent ventilator,  Ach (1 ~,g/g) was infused intrave- 
nously and  the  airway  pressure changes  continuously monitored.  The 
time of Ach administration is indicated by the arrowhead. The maximum 
percent change in airway pressure relative  to baseline  is indicated  on the 
right of the tracings.  Results are  representative of five  experiments with 
three to five animals per group. 
sulted  in  no induction  of airway reactivity  to Ach under 
the same conditions (Fig.  1). 
Characterization of the Cellular Response Accompanying Air- 
way Hyperreactivity.  Having established a model of airway 
hyperreactivity, we next characterized the cells recruited to 
the  lung  and  airways  after  antigen  challenge  (Table 1). 
Analysis of the cells in BAL and whole lung confirmed the 
marked  increase  in total  cells,  particularly  eosinophils  and 
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Figure  2.  Dose-response curves  to  intravenous Ach.  Groups of five 
BALB/c  mice were immunized with OVA and  challenged  with either 
OVA (solid circles) or saline  (open circles) aerosol.  Airway pressure (A) and 
resistance  (B) were quantitated as described  in the Materials  and Methods. 
Results represent mean +  SEM and are representative of  two separate ex- 
periments. Table  1.  Cellular  Response and Maximal Airway Pressure to Ach in Designated Experimental Groups 
Total Cells  Eosinophil  PMN  Lymphocyte  Mono/Macro 
Airway 
Group  BAL  Lung  BAL  Lung  BAL  Lung  BAL  Lung  BAL  Lung  Pressure 
X 106  %  cm H2 0 
Experiment 1 
Sham/OVA  ND  0.74  0  0.7  0  0.4  1.0  20.0  99.0  79.0  6  +  2 
OVA/sham  0.25  1.3  0  1.9  0  1.5  0  24.0  99.0  73.0  10 +  4 
OVA/OVA  2.7  5.6  63.0  20.0  2.8  0.8  9.2  30.0  25.0  49.0  36  +  3 
Experiment 2 
OVA/OVA +  anti-IL-5  1.0  3.0  1.9  0.85  1.4  18.0  11.0  30.0  86.0  43.0  22  +  8.8 
OVA/OVA  5.0  7.0  44.0  23.0  1.1  8.8  18.0  39.0  37.0  29.0  22 +  7.7 
Mice in the designated  groups  were killed  1 d after the final aerosol challenge,  and BAL and total lung cells were purified as described  in Materials 
and Methods. The percentages  of the designated  cell types were highly comparable  in two separate experiments and were derived from pooled cells 
representing five mice in each group. Maximal airway pressure  change  in response  to 1 p,g Ach/g mouse was quantitated  as described  in Materials 
and Methods and is expressed as mean +  SEM. 
lymphocytes,  in  animals  that  were  both  immunized  and 
aerosolized  with  OVA.  Lymphocyte  recruitment  in  BAL 
was biased toward CD4 + T  cells, as demonstrated by eleva- 
tion of the CD4+/CD8  + cell ratio as assessed by cytofluori- 
metric analysis  (CD4+/CD8  +  =  2.7  for sham  aerosol,  6.1 
for  OVA).  Light  microscopy  of fixed  lung  specimens  re- 
vealed a  lymphocytic  infdtrate  with  numerous  eosinophils 
around  veins  and  bronchoarterial  bundles  in  immunized 
and  aerosolized  mice  that  was  not  present  in  control  ani- 
mals  (Fig. 3). 
Cytokine  Expression  in  Mice  with  Airway  Hyperreactivity. 
Cytokine expression by immune cells recruited to the lungs 
Figure 3.  Histology  of the lung in immunized mice.  (A) BALB/c mouse  immunized  with OVA subcutaneously  and aerosolized with OVA. Note 
marked peribronchovascular  infiltrates. (B) BALB/c mouse  immunized with OVA subcutaneously  and aerosolized with saline, v, vessel; b, bronchiole. 
Hemotoxylin and eosin stained sections. ￿  (A); ￿  (B). 
112  IL-4, IL-5, and Airway Hyperreactivity Figure 4.  Cytokine transcripts from BAL cells of 
BALB/c mice immunized with  OVA  and  chal- 
lenged with aerosol saline (lane 1), immunized with 
saline and challenged  with aerosol OVA (lane 2), or 
immunized with OVA and challenged with aerosol 
OVA  (lane 3).  Concentrations  of input  cDNA 
were standardized by  equalizing amplification of 
the  constitutively expressed HPRT  transcript by 
use of a polycompetitor construct containing tan- 
demly arrayed amplification products that contain 
an irrelevant insert enlarging their size such that 
they migrate more slowly in  ethidium bromide- 
stained  agarose gels. After standardizing HPRT 
products, cytokine transcripts were amplified and compared by quantitat- 
ing amplification of the wild-type (lower  band for each amplification prod- 
uct) and the competitor (upper band for each product) products using im- 
aging  densitometry. Results  are  representative of three independent 
experiments. 
of mice with  airway hyperreactivity was quantitated  using 
both tLNA- and protein-based assays.  Using a competitive 
reverse  transcription-PCR,  approach,  transcripts  for  IL-4, 
IL-5, IL-10, and IL-13, and to a lesser extent,  IFN-',/, were 
substantially  induced  in  mice  that  had  been  both  immu- 
nized and aerosolized with  OVA (Fig.  4).  IFN-y, but not 
the Th2  cytokines, was induced by aerosol alone,  even in 
nonimmunized mice. ELISPOT assays were performed im- 
mediately after removing cells  from the lung in the absence 
of added  antigen  in  vitro  to  assess spontaneous  cytokine 
production.  Mice  immunized  and  aerosolized  with  OVA 
had 2- to 3-fold increases  in numbers  of IFN-',/-secreting 
cells  and 200-fold increases in the numbers of IL-4-secret- 
ing cells per lung compared with nonimmunized mice that 
received aerosolized OVA (Table 2). The marked elevation 
in  IL-4  production  was  consistent  with  the  significantly 
raised levels  of serum  IgE in mice immunized with  OVA 
(nonimmunized  BALB/c  mice:  <1  ~g/ml;  immunized 
BALB/c mice: 10 +  0.8 Dg/ml; P <0.05). Treatment with 
GK1.5,  a mAb that depletes  CD4 + T  cells in vivo, during 
the period of aerosolization of OVA completely abrogated 
the induction ofTh2 cytokines (data not shown). 
Effects of Cytokine Neutralization on Airway Hyperreactivity, 
Cell Recruitment, and Cytokine Expression.  To elucidate the 
role of IL-5 and eosinophils,  mice were given two neutral- 
izing anti-lL-5 mAbs weekly beginning with the first sub- 
cutaneous immunization with OVA; isotype-matched con- 
trol  antibodies  were  given  to  controls.  Despite  substantial 
reduction in eosinophil numbers  in BAL and whole lung, 
in some animals to  <1%,  airway pressures  of mice treated 
with anti-IL-5 were not substantially different than animals 
that received isotype-matched antibodies  (Fig.  5).  Abroga- 
tion of eosinophil infiltration into the lung in mice treated 
with  anti-IL-5  antibodies  was  corroborated  by  enumera- 
tion of BAL and isolated lung cells  (Table  1)  and by light 
microscopic  examination  of fixed tissue  sections  (data  not 
shown). 
In marked contrast to mice treated with anti-IL-5, mice 
treated  with  neutralizing  anti-IL-4  mAb  throughout  the 
period of immunization had substantial  blockade of airway 
hyperreactivity  (Fig.  6  A).  Treatment  of mice with  anti- 
IL-4 had  little  effect  on levels  of eosinophils  in  the  lung, 
suggesting that the effects of IL-4 are independent of effects 
on eosinophils,  in agreement with earlier studies using dif- 
ferent models (25). Importantly, when anti-IL-4 was given 
only during the period of aerosolization  of OVA,  and not 
during the  subcutaneous priming period,  there was no ef- 
fect on airway hyperreactivity (Fig. 6  B). 
Comparison of Airway  Hyperreactivity between BALB/c and 
C57BL/6 Mice.  The results using anti-IL-4 suggested that 
production of IL-4 early, during the period ofT  cell prim- 
ing, was critically associated with the later manifestation of 
airway  hyperreactivity.  BALB/c  mice,  compared  with 
C57BL/6 animals, produce enhanced amounts of IL-4 dur- 
ing priming of CD4 + T  cells (26), a characteristic that may 
underlie  the  peculiar  susceptibility  of BALB/c  mice  to 
L.  major (27).  If production  of IL-4 during  initial  antigen 
exposure  is  associated  with  airway  hyperreactivity  in  this 
model,  BALB/c  mice  might be  expected  to  generate  in- 
creased responses  compared with  other strains  of mice.  In 
side-by-side comparisons of similarly  treated animals,  BALB/c 
Table 2.  Cytokine  Protein Production of Isolated Whole-Lung Cells  from OVA-immunized and -aerosolized Mice 
Cytokines 
IFN-'y  IL-4 
Group  Cell frequency  Total cells/lung  Cell frequency  Total cells/lung 
per 106 cells  per 106 cells 
OVA/OVA  61  +  31  376 +_ 221  265  +  49  1929  +  514 
OVA/irrelevant Ag  25 +  5.8  35 +  13  77 •  13  96 +  10 
Sham/OVA  320  128  24  9.6 
Mice in the designated groups were killed 1 d after the final aerosol challenge. Purified lung cells were assessed for spontaneous secretion of IFN-~ 
and IL-4 using an ELISPOT assay as described in Materials and Methods. Data represent mean -+ SEM from three animals and are representative of 
three separate experiments. 
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Figure  5.  Effect  of IL-5 neutralization on bronchial hyperreactivity. 
Groups of BALB/c mice were immunized with OVA and challenged 
with OVA or saline aerosol. Designated groups were treated weekly with 
neutralizing anti-IL-5 or isotype control antibodies throughout the ex- 
perimental protocol. Results are expressed as mean maximum percentage 
of change in airway pressure -+ SEM relative to baseline after chal]enge 
with intravenous Ach and are representative of two comparable experi- 
ments. Percentages ofeosinophils in recovered BAL cells are depicted be- 
neath the bar graphs (% Eo). 
mice  demonstrated  consistently  greater  airway hyperreac- 
tivity than did C57BL/6 (percent change in baseline airway 
pressure 30 -+ 6 versus 7  +  3 for BALB/c versus C57BL/6, 
respectively; P  <0.05). 
Discussion 
The  presence  of activated  T  cells  in  bronchial  biopsies 
and BAL fluid from patients with asthma (3-6, 28, 29) and 
of lymphocytes in  the  airways  and  submucosa  of patients 
dying of the disease  (30, 31) have focused attention on the 
role of cells  of the acquired immune system in the patho- 
genesis  of asthma.  Activated CD4 +  T  cells  have  been  re- 
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Figure  6.  Effect  of IL-4 neutralization on bronchial hyperreactivity. 
Groups of BALB/c mice were immunized with OVA and challenged 
with OVA  or saline aerosol. Designated groups were treated weekly 
throughout the experiment with neutralizing anti-IL-4 antibody or iso- 
type control (A) or only during the period of aerosol challenge (B). R_e- 
suits are expressed as mean maximum percentage of airway pressure -+ 
SEM relative to baseline after challenge with intravenous Ach and are 
representative of two comparable experiments. Percentages ofeosinophils 
in recovered BAL cells are depicted beneath the bar graphs (% Eo). 
covered that express a range of cytokines, particularly IL-4, 
IL-5, and GM-CSF, consistent with a Th2-1ike profile (3-6). 
Allergen-specific T  cell clones established from atopic indi- 
viduals consistently produce Th2 cytokines (32),  and aller- 
gen-induced  provocation  has  caused  expression  of these 
cytokines at sites  of challenge  (33, 34).  Although activated 
T  cells  constitute  a  significant  source  of these  cytokines, 
both activated mast cells  (35,  36)  and  eosinophils  (37)  are 
capable  of contributing Th2-1ike  cytokines that  might be 
anticipated to compound pathology mediated by these cy- 
tokines in an autocrine  fashion.  Patients have been identi- 
fied  with  expanded  numbers  of Th2-1ike  cells  or  clones 
who present with atopic symptoms, including sinopulmo- 
nary pathology (38, 39).  These various data have suggested 
a model of asthma in which aberrant activation of immune 
cells  to  produce  Th2-type  cytokines  in  response  to  un- 
known respiratory antigens leads to the recruitment of mast 
cells,  T  cells,  and  eosinophils  capable  of causing  chronic 
damage to the airway. 
The murine model used in these studies constitutes a re- 
producible  system  for inducing  airway  hyperreactivity  in 
response to antigen that permits the identification of factors 
that are required for this physiologic response.  As demon- 
strated using SCID mice, the phenotype of airway hyperre- 
activity required cells  of the specific immune system. Stud- 
ies elsewhere have demonstrated that depletion  of T  cells, 
or CD4 + T  cells,  up to 1 wk before challenge successfully 
abrogated  the  airway  response  (11,  18).  As  shown  here, 
IL-4  was required  during the period  of T  cell priming to 
OVA,  since  neutralization  of IL-4  abrogated  the  physio- 
logic  response  when  administered  during  subcutaneous 
sensitization  with  antigen,  but  not  during  the  period  of 
aerosol challenge. A number of in vitro and in vivo systems 
have demonstrated that IL-4 is required for the priming of 
Th2  cells  (40),  suggesting that  CD4 +  T  cell priming with 
IL-4 is a prerequisite for the development of airway inflam- 
mation and hyperreactivity to Ach. Similar results were ob- 
served  in  studies  using  IL-4 knock-out  mice;  airway  in- 
flammation  and  bronchial  responses  to  carbachot  and 
serotonin  were  substantially  less  than  in  wild-type  mice 
(41).  The  results  here  would  extend  those  findings  to  a 
greater requirement  for IL-4 in the inductive,  rather  than 
effector, stages of airway pathology, despite the fact that we 
were able to quantitate  marked production of IL-4 during 
the time that bronchial hyperreactivity was determined. 
A  large  body of literature  has  documented  the  associa- 
tion of pulmonary eosinophil infiltration and airway hyper- 
reactivity in both asthmatic  humans  and animal models of 
airway inflammation  (1,  9, 42).  Studies from humans with 
asthma  have  demonstrated  large  quantities  of eosinophil 
cationic protein  and major basic protein  in BAL fluid and 
deposited  in  the  submucosa  of airway biopsies,  indicating 
active  eosinophil  degranulation  (9,  42).  Eosinophil  prod- 
ucts are postulated  to contribute  to airway hyperreactivity 
through damage to the airway epithelium, leaving underly- 
ing  smooth  muscle  more  susceptible  to  nonspecific  con- 
tractile mediators, or perhaps by contributing to the airway 
remodeling  and  narrowing  observed  in  patients  with 
114  IL-4, IL-5, and Airway Hyperreactivit 3, chronic disease  (43, 44). Although a role for eosinophils in 
contributing to chronic airway changes or late-phase  asth- 
matic responses is not excluded,  the data here do not sup- 
port a role for either IL-5 or eosinophils in mediating the 
acute airway hyperreactivity seen in this model.  Studies  of 
intestinal helminth infection, another system in which eosi- 
nophils are prevalent, have also been unable to define a role 
for eosinophils  in mediating  either  host defense or patho- 
logic responses (45). 
The demonstration that IL-4 was required at the time of 
parenteral  sensitization  but  not  at  the  time  of challenge 
leaves  unanswered  the  source  of the  early  IL-4  and  the 
mechanism by which airway effects are mediated.  Transfer 
of wild-type CD4 + T  cells  into IL-4 knock-out mice sug- 
gested that CD4 + T  cells  themselves were capable of gen- 
erating the IL-4 required for Th2-1ike responses in the ab- 
sence  of mast  cells  or basophils  (46).  Recent  studies  have 
focused attention on a subset of CD4 + T  cells  restricted by 
nonpolymorphic  class  I  molecules,  including  CD1  (47), 
that generated essentially all of the IL-4 produced after ad- 
ministration  of anti-CD3  or superantigens  (48).  These  T 
cells show a marked bias toward expression  of V[38 T  cell 
receptors  (49).  Interestingly,  V]38 +  T  cells  were  demon- 
strated both to expand after immunization of BALB/c mice 
with OVA and to be capable of transferring airway hyper- 
reactivity to naive recipients (50), raising the possibility that 
this  unusual  CD4 +  T  cell population  might contribute  to 
the development of airway hyperreactivity. 
The  effects  of neutralization  of IL-4 during the  aerosol 
phase of the model suggests that IL-4 is not required during 
the  effector  phase  of airway  hyperreactivity.  IL-4  is  re- 
quired  for IgE isotype switching,  and cross-linking of Fce 
receptors on mast cells by IgE would be consistent with the 
activated mast cell phenotype seen  in asthma.  Indeed,  the 
mast cell-deficient  W/W  ~ mouse  had  diminished  eosino- 
phil  infltration  when  used in a  comparable airway model 
(13).  However,  IgE-deficient mice were capable of devel- 
oping anaphylaxis and pulmonary function changes compa- 
rable  to  wild-type  mice  (51),  suggesting  additional  path- 
ways  capable  of  mediating  pathologic  responses.  The 
critical role for IL-4 during antigen priming in establishing 
the downstream cascade required for airway hyperreactivity 
suggests that interdictions capable of reprogramnfing CD4 + 
subset development to common respiratory allergens might 
constitute  effective  vaccine  approaches  to  the  control  of 
asthma.  Such interventions  are  amenable  to  testing  in the 
animal model used for these studies. 
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